Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02934815
Other study ID # FPCEUP/BreastCancerCare
Secondary ID
Status Recruiting
Phase N/A
First received October 12, 2016
Last updated October 13, 2016
Start date January 2015
Est. completion date January 2017

Study information

Verified date October 2016
Source Universidade do Porto
Contact n/a
Is FDA regulated No
Health authority Portugal: Data Protection Agency
Study type Interventional

Clinical Trial Summary

To test the feasibility of supportive-expressive group intervention (SEGT) for women with primary breast cancer and to provide a preliminary test of its efficacy.


Description:

This study aims to compare the efficacy of a 16-sessions group intervention (Supportive-Expressive group therapy) versus control group (no intervention) in women with primary breast cancer.

This study tries to evaluate the efficacy of SEGT on breast cancer patients' emotion regulation, social support, caregiving, and marital satisfaction, and its improvement on breast cancer patients' life quality. This study also intents to explore the moderating role of attachment on these associations.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender Female
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria:

- diagnosis of primary breast cancer

Exclusion Criteria:

- attendance at a cancer support group or individual psychotherapy

- diagnosis of recurrent breast cancer

- severe psychiatric disorder

- history of drug or alcohol abuse

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Other:
Supportive-expressive group therapy
The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.

Locations

Country Name City State
Portugal Tânia Brandão Porto

Sponsors (5)

Lead Sponsor Collaborator
Universidade do Porto Centro Hospitalar De São João, E.P.E., Centro Hospitalar de Vila Nova de Gaia/Espinho, Fundação para a Ciência e a Tecnologia, Mama Help - Support Centre for Breast Cancer Patients

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in group climate across time The Group Climate Questionnaire T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Primary Change in quality of life across time The World Health Organization Quality of Life - BREF T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in emotion suppression across time The Emotion Regulation Questionnaire T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in emotional self-efficacy across time The Stanford Emotional Self-Efficacy Scale-Cancer T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in cognitive emotion across time The Cognitive Emotion Regulation Questionnaire T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in social support across time The Multidimensional Scale of Perceived Social Support T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in caregiving across time The Caregiving Questionnaire T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
Secondary Change in marital relationship across time Relationship Assessment Scale T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A